文献速递白血病

年轻急性髓系白血病患者化疗疗程数优化:三疗程与四疗程比较

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
PubMed 文献 · J Clin Oncol · 2020-12-23

英国AML17试验将非高危年轻AML患者随机分配至三或四疗程化疗,发现四疗程可改善5年累积复发率(50% vs 58%)和无复发生存率(43% vs 36%),但总生存无显著获益(63% vs 57%)。四疗程的获益仅限于第四疗程为Ara-C时,且对MRD阳性或阴性患者均无影响。

要点

  • 第四疗程为Ara-C时复发获益显著;MRD状态不影响第四疗程效果。

核心结论

  • 四疗程高危剂量Ara-C降低累积复发率并改善无复发生存,但未显著改善总生存。
  • 三疗程对四疗程的非劣效性未确立。
  • 亚组分析提示无FLT3或NPM1突变、其他基因突变<3个或初诊白细胞<10×10^9/L者可能从第四疗程获得生存获益。

研究设计与样本

  • 英国国家癌症研究所AML17随机对照试验,纳入非高危年轻AML患者。
  • 患者接受两个基于柔红霉素和阿糖胞苷的诱导疗程,通常联合吉妥珠单抗奥唑米星。
  • 缓解后1017例患者随机分配至第三疗程MACE(安吖啶、阿糖胞苷、依托泊苷)加第四疗程MidAc(米托蒽醌、阿糖胞苷),修正后改为1或2个疗程大剂量Ara-C。
  • 主要终点为累积复发率、无复发生存率和总生存率。

主要发现

  • 第四疗程为Ara-C时复发获益显著。
  • 探索性分析中,第四疗程对MRD阳性或阴性患者均无影响。

关键数值与推荐

  • 三疗程对四疗程的非劣效性未确立。

临床怎么用

  • 对非高危年轻AML患者,四疗程大剂量Ara-C可考虑用于降低复发风险,但需权衡无总生存获益。
  • 第四疗程为Ara-C时复发获益更明确。
  • 可根据FLT3/NPM1突变状态、其他基因突变数目及初诊白细胞水平个体化决定是否增加第四疗程。

局限性

  • 总生存差异未达统计学显著性,三疗程非劣效性未确立。
  • 第四疗程的获益仅限于第四疗程为Ara-C时。
  • 探索性亚组分析结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of three versus four courses. PATIENTS AND METHODS: Patients received two induction courses based on daunorubicin and cytarabine (Ara-C), usually with gemtuzumab ozogamicin. Following remission, 1,017 patients were randomly assigned to a third course, MACE (amsacrine, Ara-C, and etoposide), plus a fourth course of MidAc (mitoxantrone and Ara-C) and following an amendment to one or two courses of high-dose Ara-C. Primary end points were cumulative incidence of relapse (CIR), relapse-free survival (RFS), and overall survival (OS). Outcomes were correlated with patient characteristics, mutations, cytogenetics, induction treatments, and measurable residual disease (MRD) postinduction. RESULTS: In logrank analyses, CIR and RFS at 5 years were improved in recipients of four courses (50% v 58%: hazard ratio [HR] 0.81 [0.69-0.97], P = .02 and 43% v 36%: HR 0.83 [0.71-0.98], P = .03, respectively). While OS was not significantly better (63% v 57%: HR 0.84 [0.69-1.03], P = .09), the noninferiority of three courses to four courses was not established. The impact on relapse was only significant when the fourth course was Ara-C. In exploratory analyses, although MRD impacted survival, a fourth course had no effect in either MRD-positive or MRD-negative patients. A fourth course was beneficial in patients who lacked a mutation of FLT3 or NPM1, had < 3 mutations in other genes, or had a presenting WBC of < 10 × 109 L-1. CONCLUSION: Although a fourth course of high-dose Ara-C reduced CIR and improved RFS, it did not result in a significant OS benefit. Subsets including those with favorable cytogenetics, those lacking a mutation of FLT3 or NPM1, or those with < 3 other mutations may derive survival benefit.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Burnett AK, Russell NH, Hills RK, et al. Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. J Clin Oncol. 2020. PMID: 33356418. doi:10.1200/JCO.20.01170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。